EGFR and glioblastoma: Notably, cluster 22 was enriched (38%) for secondary GBM, tumours that progress from lower-grade precursors, arise in younger patients (Miller and Perry, 2007), and feature IHD1 mutations (Yan et al, 2009), but lack EGFR amplification (Louis et al, 2007).